Detecting bladder cancer using urine samples
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer
This study is looking at a new way to find and track bladder cancer by testing urine samples for cancer-related DNA, and it's designed for patients with bladder cancer or those at risk, to help improve their treatment and care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10880419 on NIH RePORTER |
What this research studies
This research focuses on improving the detection and monitoring of bladder cancer by analyzing tumor nucleic acids found in urine. The study aims to develop a novel method called urine tumor DNA Cancer Personalized Profiling by Deep Sequencing (uCAPP-Seq), which has shown promising results in identifying bladder cancer with high sensitivity and specificity. Patients with bladder cancer or those at risk will provide urine samples, which will be analyzed to assess the effectiveness of this new diagnostic tool. The goal is to enhance personalized treatment approaches and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with bladder cancer or those at high risk for developing the disease.
Not a fit: Patients with other types of cancer or those without any risk factors for bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and personalized detection and monitoring of bladder cancer, potentially improving treatment outcomes for patients.
How similar studies have performed: Other research has shown success with similar molecular diagnostic approaches, indicating a promising avenue for bladder cancer detection.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Diehn, Maximilian — Stanford University
- Study coordinator: Diehn, Maximilian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.